Knockdown of SNORA47 Inhibits the Tumorigenesis of NSCLC via Mediation of PI3K/Akt Signaling Pathway

Yu, Huiqing; Tian, Ling; Ling, Yang; Liu, Shihong; Wang, Sixiong; Gong, Jian

doi:10.3389/fonc.2021.620213

Cited by 12 publications

(8 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Emerging evidence suggests snoRNA's involvement in metabolism, diabetes, cancer, and heart development (20,21,23,34). Specifically, dysregulation of SNORA47, SNORA74A, and SNORNA19 was previously described to be differentially expressed in different cancers (35)(36)(37). Further, SNORA74A was differentially expressed in the myocardium derived from infants with tetralogy of Fallot (38).…”

Section: Discussionmentioning

confidence: 96%

Spaceflight-Associated Changes of snoRNAs in Peripheral Blood Mononuclear Cells and Plasma Exosomes—A Pilot Study

Kumar

Rajan

Bisserier

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

During spaceflight, astronauts are exposed to various physiological and psychological stressors that have been associated with adverse health effects. Therefore, there is an unmet need to develop novel diagnostic tools to predict early alterations in astronauts’ health. Small nucleolar RNA (snoRNA) is a type of short non-coding RNA (60–300 nucleotides) known to guide 2′-O-methylation (Nm) or pseudouridine (ψ) of ribosomal RNA (rRNA), small nuclear RNA (snRNA), or messenger RNA (mRNA). Emerging evidence suggests that dysregulated snoRNAs may be key players in regulating fundamental cellular mechanisms and in the pathogenesis of cancer, heart, and neurological disease. Therefore, we sought to determine whether the spaceflight-induced snoRNA changes in astronaut’s peripheral blood (PB) plasma extracellular vesicles (PB-EV) and peripheral blood mononuclear cells (PBMCs). Using unbiased small RNA sequencing (sRNAseq), we evaluated changes in PB-EV snoRNA content isolated from astronauts (n = 5/group) who underwent median 12-day long Shuttle missions between 1998 and 2001. Using stringent cutoff (fold change > 2 or log2-fold change >1, FDR < 0.05), we detected 21 down-and 9—up-regulated snoRNAs in PB-EVs 3 days after return (R + 3) compared to 10 days before launch (L-10). qPCR validation revealed that SNORA74A was significantly down-regulated at R + 3 compared to L-10. We next determined snoRNA expression levels in astronauts’ PBMCs at R + 3 and L-10 (n = 6/group). qPCR analysis further confirmed a significant increase in SNORA19 and SNORA47 in astronauts’ PBMCs at R + 3 compared to L-10. Notably, many downregulated snoRNA-guided rRNA modifications, including four Nms and five ψs. Our findings revealed that spaceflight induced changes in PB-EV and PBMCs snoRNA expression, thus suggesting snoRNAs may serve as potential novel biomarkers for monitoring astronauts’ health.

show abstract

Section: Discussionmentioning

confidence: 96%

Spaceflight-Associated Changes of snoRNAs in Peripheral Blood Mononuclear Cells and Plasma Exosomes—A Pilot Study

Kumar

Rajan

Bisserier

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Since SnoRNA is involved in the development of cancer in so many ways, many researchers are eager to explore its potential as a target for cancer treatment. As mentioned above, knocking down SNORA42 can prevent NSCLC to some extent, and may be an effective therapeutic target [40].…”

Section: Potential Therapeutic Value Of Snornas For Cancermentioning

confidence: 96%

“…Some snoRNAs are closely related to these two signaling pathways. Knocking down SNORA47 can signi cantly inhibit the occurrence of NSCLC by inhibiting the PI3K-AKT signaling pathway [40]. SnoRNA ACA11 can activate PI3K-AKT pathway to promote cell growth, migration and invasion, and participate in the occurrence of HCC [41].…”

Section: Molecular Mechanism Of Cancer Induced By Snornamentioning

confidence: 99%

Knowledge mapping and current trends of global research on snoRNA in the field of cancer

Hou

Wang

et al. 2023

Preprint

View full text Add to dashboard Cite

Backgroud: Cancer is a major hazard to human health. Recently, small nucleolar RNA (snoRNA) has been found to be involved in the occurrence and development of cancer, which has potential diagnostic, prognostic and therapeutic value. The purpose of this study is to use the bibliometrics method to sort out and study the previous published papers. Methods We collected articles from the Web of Science Core Collection database in the field of snoRNA and cancer. Then, we used VOSviewer, Citespace, WPS and other software to visualize authors, Finally, we interpreted the data and analyzed the hotspots and frontiers of the research. Results The number of articles in this field was low in the early period, but exploded since 2008. According to the calculation of Prince's law, we believed that a stable cooperative group had been formed in this field. Chu, Liang and Montanaro, Lorenzo published the most papers, while Jiang, Feng were cited the most times. Three institutions published the most articles, namely Wuhan Univ, China Med Univ and Guangxi Med Univ. The journal with the most articles was Oncotarget. Through the analysis of countries/regions, it was found that the country with the most published articles was China. The analysis of keywords and burst words indicated that early studies mainly focused on the molecular mechanisms, but in recent years, it has gradually shifted to the direction of diagnosis, prognosis and therapy. Conclusion The research of snoRNA and cancer was a hot topic in recent years. Through analysis, we found that snoRNA was involved in the molecular mechanism of cancer development and can be used as a biomarker for clinical diagnosis and prognosis.

show abstract

“…However, most of the in vitro studies were performed using primary tumours with a bone tropism, suggesting a role of snoRNAs in metastatic progression in bone. Indeed, experimental modulation of snoRNAs has been shown to regulate migration/invasion in different cancer cell lines derived from prostate (SNORA42, SNORA55) [88,89], breast (SNORA7B, SNORA71A, SNORD50A/B) [90][91][92], lung (SNORA42, SNORA47, SNORA71A, SNORD38, SNORD78) [86,[93][94][95][96], and ovarian cancer (SNORA70E, SNORA72, SNORD89) [97][98][99]. In addition, some of these snoRNAs have also been shown to modulate stemness capabilities in these different cancer types having a bone metastatic tropism (SNORD78, SNORA42, SNORD89, SNORA72, SNORA71A).…”

Section: Mirna and Snorna Expression In Cancer Cells And Their Roles ...mentioning

confidence: 99%

MiRNAs and snoRNAs in Bone Metastasis: Functional Roles and Clinical Potential

Puppo

Jaafar

Diaz

et al. 2022

Cancers

View full text Add to dashboard Cite

Bone is a frequent site of metastasis. Bone metastasis is associated with a short-term prognosis in cancer patients, and current treatments aim to slow its growth, but are rarely curative. Thus, revealing molecular mechanisms that explain why metastatic cells are attracted to the bone micro-environment, and how they successfully settle in the bone marrow—taking advantage over bone resident cells—and grow into macro-metastasis, is essential to propose new therapeutic approaches. MicroRNAs and snoRNAs are two classes of small non-coding RNAs that post-transcriptionally regulate gene expression. Recently, microRNAs and snoRNAs have been pointed out as important players in bone metastasis by (i) preparing the pre-metastatic niche, directly and indirectly affecting the activities of osteoclasts and osteoblasts, (ii) promoting metastatic properties within cancer cells, and (iii) acting as mediators within cells to support cancer cell growth in bone. This review aims to highlight the importance of microRNAs and snoRNAs in metastasis, specifically in bone, and how their roles can be linked together. We then discuss how microRNAs and snoRNAs are secreted by cancer cells and be found as extracellular vesicle cargo. Finally, we provide evidence of how microRNAs and snoRNAs can be potential therapeutic targets, at least in pre-clinical settings, and how their detection in liquid biopsies can be a useful diagnostic and/or prognostic biomarker to predict the risk of relapse in cancer patients.

show abstract

Knockdown of SNORA47 Inhibits the Tumorigenesis of NSCLC via Mediation of PI3K/Akt Signaling Pathway

Cited by 12 publications

References 25 publications

Spaceflight-Associated Changes of snoRNAs in Peripheral Blood Mononuclear Cells and Plasma Exosomes—A Pilot Study

Spaceflight-Associated Changes of snoRNAs in Peripheral Blood Mononuclear Cells and Plasma Exosomes—A Pilot Study

Knowledge mapping and current trends of global research on snoRNA in the field of cancer

MiRNAs and snoRNAs in Bone Metastasis: Functional Roles and Clinical Potential

Contact Info

Product

Resources

About